{
    "hands_on_practices": [
        {
            "introduction": "The diagnostic journey for a child with a renal mass begins with synthesizing diverse clinical data. This exercise will guide you through building a quantitative model to estimate the probability of Wilms tumor, starting from an age-based prior probability and updating it with evidence from imaging and laboratory tests . By applying the principles of Bayesian inference, you will gain hands-on experience in how clinicians formalize diagnostic reasoning and manage uncertainty.",
            "id": "5218770",
            "problem": "You are asked to construct a quantitative Bayesian inference program to estimate the posterior probability that a pediatric patient with a unilateral renal mass has Wilms tumor (nephroblastoma), given imaging and laboratory findings. The foundation must begin from definitions of conditional probability and Bayes rule. The cohort context is restricted to children with a unilateral renal mass identified on ultrasound. The model must start with an age-based prior probability and update using likelihood ratios derived from imaging and laboratory evidence under the assumption that the individual pieces of evidence are conditionally independent given the disease status.\n\nFundamental base to use:\n- Definition of conditional probability: for events $A$ and $B$, $P(A \\mid B) = \\frac{P(A \\cap B)}{P(B)}$.\n- Bayes rule: for hypothesis $H$ and data $D$, $P(H \\mid D) = \\frac{P(D \\mid H) P(H)}{P(D)}$.\n- Odds form of Bayes rule with likelihood ratios: if $O(H)$ denotes odds $O(H) = \\frac{P(H)}{1 - P(H)}$ and $\\operatorname{LR}$ denotes the likelihood ratio, then posterior odds satisfy $O(H \\mid D) = O(H) \\times \\operatorname{LR}(D)$ when evidence $D$ is modeled as conditionally independent components, each contributing multiplicatively via its own likelihood ratio.\n\nAge-based prior probability $P(H)$ of Wilms tumor $H$ in this cohort (children with unilateral renal mass on ultrasound) is specified as a piecewise function of age $a$ in years:\n- If $0 \\le a < 1$, then $P(H) = 0.65$.\n- If $1 \\le a < 2$, then $P(H) = 0.75$.\n- If $2 \\le a < 6$, then $P(H) = 0.85$.\n- If $6 \\le a < 10$, then $P(H) = 0.55$.\n- If $a \\ge 10$, then $P(H) = 0.20$.\n\nImaging and laboratory findings to be integrated:\n- Imaging intrarenal origin (claw sign) presence contributes a likelihood ratio:\n  - If present, $\\operatorname{LR} = 3.5$.\n  - If absent, $\\operatorname{LR} = 0.3$.\n- Coarse calcifications on imaging:\n  - If present, $\\operatorname{LR} = 0.4$.\n  - If absent, $\\operatorname{LR} = 1.8$.\n- Renal vein or inferior vena cava thrombus:\n  - If present, $\\operatorname{LR} = 4.0$.\n  - If absent, $\\operatorname{LR} = 0.8$.\n- Hematuria (blood in urine):\n  - If present, $\\operatorname{LR} = 2.2$.\n  - If absent, $\\operatorname{LR} = 0.9$.\n- Catecholamine metabolites (vanillylmandelic acid/homovanillic acid; VMA/HVA):\n  - If elevated, $\\operatorname{LR} = 0.1$.\n  - If normal, $\\operatorname{LR} = 1.5$.\n- Serum lactate dehydrogenase (LDH) in units per liter (U/L), modeled as continuous evidence using normal distributions under Wilms tumor versus other diagnoses in this cohort. The likelihood ratio for LDH value $x$ is:\n  $$\\operatorname{LR}_{\\mathrm{LDH}}(x) = \\frac{f_{\\mathrm{W}}(x)}{f_{\\neg \\mathrm{W}}(x)},$$\n  where\n  $$f_{\\mathrm{W}}(x) = \\frac{1}{\\sigma_{\\mathrm{W}} \\sqrt{2\\pi}} \\exp\\left(-\\frac{(x - \\mu_{\\mathrm{W}})^2}{2\\sigma_{\\mathrm{W}}^2}\\right), \\quad \\mu_{\\mathrm{W}} = 420, \\ \\sigma_{\\mathrm{W}} = 60,$$\n  $$f_{\\neg \\mathrm{W}}(x) = \\frac{1}{\\sigma_{\\neg \\mathrm{W}} \\sqrt{2\\pi}} \\exp\\left(-\\frac{(x - \\mu_{\\neg \\mathrm{W}})^2}{2\\sigma_{\\neg \\mathrm{W}}^2}\\right), \\quad \\mu_{\\neg \\mathrm{W}} = 360, \\ \\sigma_{\\neg \\mathrm{W}} = 70.$$\n\nComputational tasks:\n1. Implement the posterior odds computation from the age-based prior and the product of likelihood ratios for the provided evidence, assuming conditional independence of evidence given the disease state.\n2. Convert posterior odds $O(H \\mid D)$ to posterior probability $P(H \\mid D)$ by\n   $$P(H \\mid D) = \\frac{O(H \\mid D)}{1 + O(H \\mid D)}.$$\n3. Express the final posterior probability for each test case as a decimal, rounded to six decimal places.\n\nTest suite to be used by the program without user input (ordered list of cases):\n- Case $1$: $a = 3.5$ years, intrarenal origin present, calcifications absent, thrombus present, hematuria present, catecholamines normal, $\\mathrm{LDH} = 480$ U/L.\n- Case $2$: $a = 0.8$ years, intrarenal origin absent, calcifications present, thrombus absent, hematuria absent, catecholamines elevated, $\\mathrm{LDH} = 330$ U/L.\n- Case $3$: $a = 7.0$ years, intrarenal origin present, calcifications absent, thrombus absent, hematuria present, catecholamines normal, $\\mathrm{LDH} = 410$ U/L.\n- Case $4$: $a = 11.0$ years, intrarenal origin present, calcifications absent, thrombus present, hematuria absent, catecholamines normal, $\\mathrm{LDH} = 450$ U/L.\n- Case $5$: $a = 2.5$ years, intrarenal origin absent, calcifications present, thrombus absent, hematuria absent, catecholamines elevated, $\\mathrm{LDH} = 420$ U/L.\n\nFinal output format:\n- Your program should produce a single line of output containing the posterior probabilities for the test suite as a comma-separated list enclosed in square brackets, with each value rounded to six decimal places (e.g., $[0.123456,0.654321,0.500000]$).",
            "solution": "The problem requires the construction of a Bayesian inference model to estimate the posterior probability of a pediatric patient having a Wilms tumor, denoted as hypothesis $H$, given a set of clinical and laboratory evidence, denoted as data $D$. The analysis is grounded in the principles of conditional probability and Bayes' rule, applied sequentially.\n\nThe foundational principle is Bayes' rule, which relates the conditional probabilities of two events. For a hypothesis $H$ and evidence $D$, it is stated as:\n$$P(H \\mid D) = \\frac{P(D \\mid H) P(H)}{P(D)}$$\nwhere $P(H)$ is the prior probability of the hypothesis, $P(D \\mid H)$ is the likelihood of observing the evidence given the hypothesis is true, and $P(H \\mid D)$ is the posterior probability of the hypothesis after observing the evidence. The term $P(D)$ is the marginal probability of the evidence, acting as a normalization constant.\n\nFor diagnostic reasoning, it is often more convenient to work with odds and likelihood ratios. The odds of an event $A$ are defined as $O(A) = \\frac{P(A)}{1 - P(A)}$. Bayes' rule can be rewritten in odds form:\n$$O(H \\mid D) = \\frac{P(H \\mid D)}{1 - P(H \\mid D)} = \\frac{P(D \\mid H)}{P(D \\mid \\neg H)} \\times \\frac{P(H)}{1 - P(H)}$$\nThis simplifies to:\n$$O(H \\mid D) = \\operatorname{LR}(D) \\times O(H)$$\nwhere $O(H)$ represents the prior odds and $\\operatorname{LR}(D) = \\frac{P(D \\mid H)}{P(D \\mid \\neg H)}$ is the likelihood ratio of the evidence $D$.\n\nThe problem states that the individual pieces of evidence $D_1, D_2, \\ldots, D_n$ are conditionally independent given the disease status (presence or absence of Wilms tumor). This critical assumption allows the total likelihood ratio to be factored into the product of the individual likelihood ratios for each piece of evidence:\n$$\\operatorname{LR}_{\\text{total}} = \\operatorname{LR}(D_1) \\times \\operatorname{LR}(D_2) \\times \\cdots \\times \\operatorname{LR}(D_n)$$\nThe posterior odds are thus calculated by updating the prior odds with this composite likelihood ratio:\n$$O(H \\mid D_1, \\ldots, D_n) = O(H) \\times \\prod_{i=1}^{n} \\operatorname{LR}(D_i)$$\n\nThe steps for calculating the posterior probability for each patient case are as follows:\n\n**1. Determine the Prior Odds, $O(H)$**\nThe prior probability, $P(H)$, is a function of the patient's age $a$ in years. The problem defines a piecewise function for $P(H)$:\n- If $0 \\le a < 1$, then $P(H) = 0.65$.\n- If $1 \\le a < 2$, then $P(H) = 0.75$.\n- If $2 \\le a < 6$, then $P(H) = 0.85$.\n- If $6 \\le a < 10$, then $P(H) = 0.55$.\n- If $a \\ge 10$, then $P(H) = 0.20$.\nFrom $P(H)$, the prior odds are calculated as $O(H) = \\frac{P(H)}{1 - P(H)}$.\n\n**2. Calculate the Total Likelihood Ratio, $\\operatorname{LR}_{\\text{total}}$**\nThe total likelihood ratio is the product of the LRs for six distinct pieces of evidence: intrarenal origin, coarse calcifications, thrombus, hematuria, catecholamines, and serum LDH.\n$$\\operatorname{LR}_{\\text{total}} = \\operatorname{LR}_{\\text{origin}} \\times \\operatorname{LR}_{\\text{calc}} \\times \\operatorname{LR}_{\\text{thrombus}} \\times \\operatorname{LR}_{\\text{hematuria}} \\times \\operatorname{LR}_{\\text{cat}} \\times \\operatorname{LR}_{\\text{LDH}}$$\n\nThe LRs for the five binary/categorical findings are given directly:\n- Intrarenal origin: $\\operatorname{LR} = 3.5$ (present) or $0.3$ (absent).\n- Coarse calcifications: $\\operatorname{LR} = 0.4$ (present) or $1.8$ (absent).\n- Renal vein/IVC thrombus: $\\operatorname{LR} = 4.0$ (present) or $0.8$ (absent).\n- Hematuria: $\\operatorname{LR} = 2.2$ (present) or $0.9$ (absent).\n- Catecholamine metabolites: $\\operatorname{LR} = 0.1$ (elevated) or $1.5$ (normal).\n\nThe LR for the continuous variable, serum LDH level $x$, is the ratio of the probability density functions (PDFs) for LDH under the Wilms tumor hypothesis ($H$) versus the alternative ($\\neg H$). These are modeled as normal distributions:\n$$\\operatorname{LR}_{\\mathrm{LDH}}(x) = \\frac{f_{\\mathrm{W}}(x)}{f_{\\neg \\mathrm{W}}(x)}$$\nwhere\n$$f_{\\mathrm{W}}(x) = \\frac{1}{\\sigma_{\\mathrm{W}} \\sqrt{2\\pi}} \\exp\\left(-\\frac{(x - \\mu_{\\mathrm{W}})^2}{2\\sigma_{\\mathrm{W}}^2}\\right)$$\nwith parameters $\\mu_{\\mathrm{W}} = 420$ U/L and $\\sigma_{\\mathrm{W}} = 60$ U/L.\nAnd\n$$f_{\\neg \\mathrm{W}}(x) = \\frac{1}{\\sigma_{\\neg \\mathrm{W}} \\sqrt{2\\pi}} \\exp\\left(-\\frac{(x - \\mu_{\\neg \\mathrm{W}})^2}{2\\sigma_{\\neg \\mathrm{W}}^2}\\right)$$\nwith parameters $\\mu_{\\neg \\mathrm{W}} = 360$ U/L and $\\sigma_{\\neg \\mathrm{W}} = 70$ U/L.\n\n**3. Compute the Posterior Odds, $O(H \\mid D)$**\nThe posterior odds are found by multiplying the prior odds by the total likelihood ratio:\n$$O(H \\mid D) = O(H) \\times \\operatorname{LR}_{\\text{total}}$$\n\n**4. Convert Posterior Odds to Posterior Probability, $P(H \\mid D)$**\nFinally, the posterior odds are converted back into a probability using the relation:\n$$P(H \\mid D) = \\frac{O(H \\mid D)}{1 + O(H \\mid D)}$$\nThe resulting probability is then rounded to six decimal places as required.\n\nThis procedure will be systematically applied to each of the five test cases provided. For instance, for Case $1$ ($a=3.5$, etc.), the steps would be:\n- $a=3.5 \\implies P(H) = 0.85 \\implies O(H) = \\frac{0.85}{1-0.85} = \\frac{17}{3}$.\n- $\\operatorname{LR}_{\\text{total}} = 3.5 \\times 1.8 \\times 4.0 \\times 2.2 \\times 1.5 \\times \\operatorname{LR}_{\\text{LDH}}(480)$.\n- Calculate $\\operatorname{LR}_{\\text{LDH}}(480) = \\frac{f_{\\mathrm{W}}(480)}{f_{\\neg \\mathrm{W}}(480)}$.\n- Combine these to get $O(H|D)$ and then $P(H|D)$.\nThe implementation will formalize this logic.",
            "answer": "```python\n# The complete and runnable Python 3 code goes here.\n# Imports must adhere to the specified execution environment.\nimport numpy as np\nfrom scipy.stats import norm\n\n#\n# Execution Environment:\n# language: Python\n# version: 3.12\n# libraries:\n#     - name: numpy, version: 1.23.5\n#     - name: scipy, version: 1.11.4\n#\n\ndef solve():\n    \"\"\"\n    Solves the Bayesian inference problem for estimating Wilms tumor probability.\n    \"\"\"\n\n    # Define the likelihood ratios for categorical evidence from the problem statement.\n    LR_MAP = {\n        'origin': {'present': 3.5, 'absent': 0.3},\n        'calcifications': {'present': 0.4, 'absent': 1.8},\n        'thrombus': {'present': 4.0, 'absent': 0.8},\n        'hematuria': {'present': 2.2, 'absent': 0.9},\n        'catecholamines': {'elevated': 0.1, 'normal': 1.5}\n    }\n\n    # Define the parameters for the normal distributions of LDH levels.\n    LDH_PARAMS = {\n        'W': {'mu': 420.0, 'sigma': 60.0},\n        'not_W': {'mu': 360.0, 'sigma': 70.0}\n    }\n\n    def get_prior_prob(age: float) -> float:\n        \"\"\"\n        Calculates the age-based prior probability of Wilms tumor.\n        \"\"\"\n        if 0.0 <= age < 1.0:\n            return 0.65\n        elif 1.0 <= age < 2.0:\n            return 0.75\n        elif 2.0 <= age < 6.0:\n            return 0.85\n        elif 6.0 <= age < 10.0:\n            return 0.55\n        else:  # age >= 10.0\n            return 0.20\n\n    def calculate_ldh_lr(ldh_value: float) -> float:\n        \"\"\"\n        Calculates the likelihood ratio for a given LDH value.\n        \"\"\"\n        mu_W, sigma_W = LDH_PARAMS['W']['mu'], LDH_PARAMS['W']['sigma']\n        mu_not_W, sigma_not_W = LDH_PARAMS['not_W']['mu'], LDH_PARAMS['not_W']['sigma']\n        \n        pdf_W = norm.pdf(ldh_value, loc=mu_W, scale=sigma_W)\n        pdf_not_W = norm.pdf(ldh_value, loc=mu_not_W, scale=sigma_not_W)\n        \n        # In the unlikely event pdf_not_W is zero (or underflows),\n        # evidence for W is overwhelming. Return a very large number.\n        if pdf_not_W == 0.0:\n            return 1e12 \n            \n        return pdf_W / pdf_not_W\n\n    # Define the test cases from the problem statement.\n    test_cases = [\n        {'age': 3.5, 'origin': 'present', 'calc': 'absent', 'thrombus': 'present', 'hematuria': 'present', 'cat': 'normal', 'ldh': 480.0},\n        {'age': 0.8, 'origin': 'absent', 'calc': 'present', 'thrombus': 'absent', 'hematuria': 'absent', 'cat': 'elevated', 'ldh': 330.0},\n        {'age': 7.0, 'origin': 'present', 'calc': 'absent', 'thrombus': 'absent', 'hematuria': 'present', 'cat': 'normal', 'ldh': 410.0},\n        {'age': 11.0, 'origin': 'present', 'calc': 'absent', 'thrombus': 'present', 'hematuria': 'absent', 'cat': 'normal', 'ldh': 450.0},\n        {'age': 2.5, 'origin': 'absent', 'calc': 'present', 'thrombus': 'absent', 'hematuria': 'absent', 'cat': 'elevated', 'ldh': 420.0}\n    ]\n\n    results = []\n    for case in test_cases:\n        # Step 1: Calculate prior odds from age-based prior probability\n        prior_prob = get_prior_prob(case['age'])\n        # Handle the edge case where prior_prob could be 1, though not in this problem's data\n        if prior_prob == 1.0:\n            prior_odds = np.inf\n        else:\n            prior_odds = prior_prob / (1.0 - prior_prob)\n\n        # Step 2: Calculate the total likelihood ratio\n        lr_origin = LR_MAP['origin'][case['origin']]\n        lr_calc = LR_MAP['calcifications'][case['calc']]\n        lr_thrombus = LR_MAP['thrombus'][case['thrombus']]\n        lr_hematuria = LR_MAP['hematuria'][case['hematuria']]\n        lr_cat = LR_MAP['catecholamines'][case['cat']]\n        lr_ldh = calculate_ldh_lr(case['ldh'])\n        \n        total_lr = lr_origin * lr_calc * lr_thrombus * lr_hematuria * lr_cat * lr_ldh\n        \n        # Step 3: Compute posterior odds\n        posterior_odds = prior_odds * total_lr\n        \n        # Step 4: Convert posterior odds to posterior probability\n        posterior_prob = posterior_odds / (1.0 + posterior_odds)\n        \n        results.append(f\"{posterior_prob:.6f}\")\n\n    # Final print statement in the exact required format.\n    print(f\"[{','.join(results)}]\")\n\nsolve()\n```"
        },
        {
            "introduction": "Once a Wilms tumor is surgically resected, precise pathological staging is the cornerstone of determining the need for adjuvant therapy. This practice challenges you to apply established staging criteria to common but critical intraoperative and pathological findings, such as tumor spill or lymph node metastases . Mastering this rule-based classification is essential for understanding why patients are stratified to different treatment intensities, including the addition of radiation and multi-agent chemotherapy.",
            "id": "5218767",
            "problem": "A 3-year-old child presents with a unilateral renal mass consistent with Wilms tumor (nephroblastoma) on imaging by Computed Tomography (CT), without hematogenous metastases on chest imaging. The child undergoes radical nephrectomy with lymph node sampling. Consider each of the following intraoperative or pathologic findings as separate scenarios in a patient with favorable histology: (i) focal capsular rupture with peritoneal tumor spill that is irrigated without visible residual nodules, (ii) at least 1 regional (hilar) lymph node positive for Wilms tumor, (iii) a microscopically positive parenchymal margin with no evidence of distant spread. Using the foundational oncologic principles that staging encodes anatomic extent of disease and that adjuvant therapy is chosen to eradicate presumed residual microscopic disease based on observed patterns of spread and drug/radiation sensitivity in large cooperative trials (for example, National Wilms Tumor Study [NWTS] and Children’s Oncology Group [COG]), which option best explains why such findings are designated Stage III and justifies the treatment implications?\n\nA. Any intraoperative tumor spill, regional lymph node positivity, or residual non-hematogenous tumor confined to the abdomen signifies disease that has extended beyond the confines of a completely excised renal tumor yet remains non-distant; this defines Stage III. Because these features increase the probability of occult residual intraperitoneal or regional disease, adjuvant regional Radiation Therapy (RT) is indicated to sterilize microscopic deposits (flank RT for localized contamination or residual bed risk; whole-abdomen RT for diffuse peritoneal contamination), together with multiagent chemotherapy that includes an anthracycline (for example, vincristine, dactinomycin, and doxorubicin), rather than a 2-drug regimen.\n\nB. Negative margins and absence of hematogenous metastases define Stage II regardless of intraoperative spill or regional lymph node status if peritoneal wash cytology is negative; therefore, no RT is required and 2-drug chemotherapy (vincristine and dactinomycin) is adequate.\n\nC. Positive regional lymph nodes constitute systemic disease and therefore define Stage IV even when chest imaging is negative; this requires lung RT and intensified systemic therapy.\n\nD. Residual microscopic disease at the nephrectomy bed can be controlled by extended lymphadenectomy alone; adjuvant RT is unnecessary, and vincristine monotherapy is sufficient for favorable histology Wilms tumor in this context.",
            "solution": "The problem requires identifying the correct rationale for classifying certain findings as Stage III Wilms tumor and the resulting treatment implications. The core principle of staging is to describe the anatomic extent of disease, which then guides adjuvant therapy to manage the risk of recurrence.\n\nThe staging system for Wilms tumor, as established by cooperative groups like the Children's Oncology Group (COG), defines Stage III disease as residual, non-hematogenous tumor confined to the abdomen following surgery. The scenarios presented—(i) intraoperative tumor spill, (ii) regional lymph node metastasis, and (iii) a microscopically positive surgical margin—are all classic examples of this. Each one signifies that tumor cells have extended beyond the confines of a completely resected kidney and pose a significant risk of locoregional recurrence.\n\n-   **Tumor spill** contaminates the peritoneal cavity with malignant cells.\n-   **Positive lymph nodes** represent regional metastatic spread.\n-   **Positive margins** mean microscopic tumor was left at the resection site.\n\nGiven this higher risk of recurrence, therapy must be intensified compared to Stage I or II disease. Standard-of-care for favorable histology Stage III Wilms tumor involves two key components:\n1.  **Adjuvant Radiation Therapy (RT)**: This is directed at the abdomen (e.g., flank radiation for the tumor bed, or whole-abdomen radiation for diffuse spill) to eradicate microscopic residual disease.\n2.  **Intensified Chemotherapy**: The standard 2-drug regimen (vincristine, dactinomycin) is augmented with an anthracycline (doxorubicin), creating a more potent 3-drug regimen to improve systemic control.\n\nWith this framework, we can evaluate the options:\n\n-   **A**: This option correctly identifies the findings as defining Stage III disease (extended beyond the kidney but non-distant) and accurately describes the therapeutic consequence: adjuvant regional RT and a 3-drug chemotherapy regimen including an anthracycline. This aligns perfectly with modern treatment protocols.\n-   **B**: This option is incorrect because tumor spill and regional lymph node involvement are explicit criteria for upstaging to Stage III, not Stage II. The proposed 2-drug therapy without RT would be inadequate.\n-   **C**: This option incorrectly defines regional lymph node positivity as Stage IV disease. Stage IV is reserved for distant, hematogenous metastases (e.g., to the lungs). Regional nodal spread is the definition of Stage III.\n-   **D**: This option is incorrect on multiple fronts. Adjuvant RT is essential for a positive margin, and vincristine monotherapy is a grossly insufficient treatment for any stage of Wilms tumor.\n\nTherefore, option A provides the most accurate and comprehensive explanation.",
            "answer": "$$\n\\boxed{A}\n$$"
        },
        {
            "introduction": "Effective cancer treatment requires a delicate balance between therapeutic efficacy and patient safety, a principle embodied in chemotherapy dosing. This final exercise focuses on the practical calculation of a drug dose for a child, using the standard method of scaling to body surface area ($BSA$) while adhering to a dose cap designed to limit toxicity . This hands-on calculation solidifies your understanding of a fundamental pharmacokinetic task performed daily in pediatric oncology.",
            "id": "5218814",
            "problem": "A child with Wilms tumor (nephroblastoma) is scheduled to receive vincristine as part of a standard pediatric oncology regimen. In pediatric oncology, dosing of many cytotoxic agents is scaled to body surface area (BSA) to approximate interpatient similarity in systemic exposure because physiological determinants of distribution and clearance (for example, hepatic and renal blood flow) correlate more closely with body surface area than with body mass in children. Consider a dosing scheme that specifies a dosing intensity of vincristine of $1.5\\ \\mathrm{mg/m^2}$ with a protocol-defined maximum single dose cap to mitigate dose-dependent neurotoxicity of $2\\ \\mathrm{mg}$. The child’s body surface area, calculated by a standard method, is $1.4\\ \\mathrm{m^2}$. Starting from the fundamental principle that when a drug is dosed by body surface area the total dose should scale linearly with body surface area to preserve exposure across patients, construct the expression for the administered dose that incorporates both linear BSA scaling and the maximum single-dose cap. Then compute the numerical value of the administered vincristine dose for this child. Round your final answer to three significant figures and express the final dose in milligrams (mg).",
            "solution": "The foundational pharmacologic principle in pediatric oncology for cytotoxic agents is that systemic exposure, and thus toxicity and efficacy, are more closely related to body surface area (BSA) than to body mass. Therefore, to approximate equivalent exposure across patients of different sizes, the total administered dose is scaled linearly with BSA. If the dosing intensity is $I$ in $\\mathrm{mg}/\\mathrm{m}^2$ and the patient’s body surface area is $A$ in $\\mathrm{m}^2$, dimensional analysis dictates that the linearly scaled dose is $I \\times A$ in $\\mathrm{mg}$. The relationship can be shown as:\n$ [I] = \\mathrm{mg}/\\mathrm{m}^2, \\quad [A] = \\mathrm{m}^2 \\Rightarrow [I \\times A] = \\mathrm{mg} $.\nFor vincristine, to limit dose-dependent neurotoxicity, clinical protocols impose a maximum single-dose cap. Let $C$ denote the cap in $\\mathrm{mg}$. The administered dose $D$ that respects both linear BSA scaling and the cap is the lesser of the linearly scaled dose and the cap, which can be written as\n$$\nD = \\min\\{I \\times A,\\ C\\}.\n$$\nWe now identify the given quantities: $I = 1.5\\ \\mathrm{mg/m^2}$, $A = 1.4\\ \\mathrm{m^2}$, and $C = 2\\ \\mathrm{mg}$. Compute the linearly scaled dose:\n$$\nI \\times A = \\left(1.5\\ \\mathrm{mg}/\\mathrm{m}^2\\right)\\left(1.4\\ \\mathrm{m}^2\\right) = 2.1\\ \\mathrm{mg}.\n$$\nCompare this to the cap $C = 2\\ \\mathrm{mg}$. Since $2.1\\ \\mathrm{mg} > 2\\ \\mathrm{mg}$, the administered dose is constrained by the cap:\n$$\nD = \\min\\{2.1\\ \\mathrm{mg},\\ 2\\ \\mathrm{mg}\\} = 2\\ \\mathrm{mg}.\n$$\nRounding to three significant figures and expressing the value in milligrams yields $2.00\\ \\mathrm{mg}$.",
            "answer": "$$\\boxed{2.00}$$"
        }
    ]
}